Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Angionetics, Inc. (CRXM) Starts Presentation at LD Micro Conference

The newly-formed Angionetics, Inc., a majority-owned subsidiary of Taxus Cardium Pharmaceuticals Group, is an angiogenesis gene therapy company focused on the development and commercialization of novel DNA-based therapeutics that are designed to promote the heart’s innate natural capacity to modulate the formation and growth of cardiac microvascular circulation to enhance blood flow (perfusion) in patients with a variety of ischemia-driven disease conditions and refractory angina and myocardial ischemia due to cardiac microvascular insufficiency (CMI), and other cardiovascular disease conditions.  For more information, visit the company’s website at or

The three-day LD Micro Invitational in Bel Air, California, features company presentations from more than 200 select high-potential small-cap companies spanning multiple industries. Institutional and retail investors in attendance also have access to numerous networking opportunities and social events to learn more about these companies. For more information on LD Micro, visit
This entry was posted in LD Micro Conference. Bookmark the permalink.

Comments are closed.